Kamat AM - Search Results

1

100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19.

Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, Meeks JJ, Bivalacqua TJ, Gontero P, Steinberg GD, McConkey D, Babjuk M, Alfred Witjes J, Kamat AM. Lobo N, et al. Among authors: kamat am. Nat Rev Urol. 2021 Oct;18(10):611-622. doi: 10.1038/s41585-021-00481-1. Epub 2021 Jun 15. Nat Rev Urol. 2021. PMID: 34131332 Free PMC article. Review.

2

Immunotherapy for bladder cancer.

Kamat AM, Lamm DL. Kamat AM, et al. Curr Urol Rep. 2001 Feb;2(1):62-9. doi: 10.1007/s11934-001-0027-7. Curr Urol Rep. 2001. PMID: 12084297 Review.

3

Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8.

Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Karashima T, et al. Clin Cancer Res. 2003 Jul;9(7):2786-97. Clin Cancer Res. 2003. PMID: 12855659

4

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. Kamat AM, et al. Mol Cancer Ther. 2004 Mar;3(3):279-90. Mol Cancer Ther. 2004. PMID: 15026548

5

Focus on bladder cancer.

Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Dinney CP, et al. Among authors: kamat am. Cancer Cell. 2004 Aug;6(2):111-6. doi: 10.1016/j.ccr.2004.08.002. Cancer Cell. 2004. PMID: 15324694 Free article. Review. No abstract available.

6

Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?

Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Spiess PE, et al. Among authors: kamat am. Cancer. 2006 Oct 1;107(7):1503-10. doi: 10.1002/cncr.22181. Cancer. 2006. PMID: 16944534 Free article.

7

Contemporary intravesical treatment options for urothelial carcinoma of the bladder.

Brassell SA, Kamat AM. Brassell SA, et al. Among authors: kamat am. J Natl Compr Canc Netw. 2006 Nov;4(10):1027-36. doi: 10.6004/jnccn.2006.0086. J Natl Compr Canc Netw. 2006. PMID: 17112451 Review.

8

Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Papageorgiou A, et al. Mol Cancer Ther. 2006 Dec;5(12):3032-41. doi: 10.1158/1535-7163.MCT-05-0474. Mol Cancer Ther. 2006. PMID: 17172406

9

Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.

Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Wright JL, et al. Among authors: kamat am. J Urol. 2007 Dec;178(6):2302-6; discussion 2307. doi: 10.1016/j.juro.2007.08.038. Epub 2007 Oct 15. J Urol. 2007. PMID: 17936803

10

Considerations on the use of diagnostic markers in management of patients with bladder cancer.

Agarwal PK, Black PC, Kamat AM. Agarwal PK, et al. Among authors: kamat am. World J Urol. 2008 Feb;26(1):39-44. doi: 10.1007/s00345-007-0232-1. Epub 2007 Dec 19. World J Urol. 2008. PMID: 18092171 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

518 results

Search Page